Evidence map›Paper›PMID 26448927›Full record

ArticleBioMed research international2015

Ki-67 Expression in CRC Lymph Node Metastasis Does Not Predict Survival.

Sandra F Martins, Ricardo Amorim, Sílvia Coelho Mota, Luís Costa, Fernando Pardal, Mesquita Rodrigues, Adhemar Longatto-Filho

Abstract read
In one paragraph

Article in BioMed research international, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Proliferative Index (Ki67) for Prediction in Breast Duct CarcinomasAsian Pacific journal of cancer prevention : APJCP · 2018
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Sandra F MartinsLife and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Campus of Gualtar, 4710-057 Braga, Portugal ; ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Campus of Gualtar, 4710-057 Braga, Portugal ; Surgery Department, Hospitalar Center Trás-os-Montes e Alto Douro, Unidade Hospitalar de Chaves, Avenida Dr. Francisco Sá Carneiro, 5400-279 Chaves, Portugal.
Ricardo AmorimLife and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Campus of Gualtar, 4710-057 Braga, Portugal ; ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Campus of Gualtar, 4710-057 Braga, Portugal.
Sílvia Coelho MotaLife and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Campus of Gualtar, 4710-057 Braga, Portugal.
Luís CostaLife and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Campus of Gualtar, 4710-057 Braga, Portugal.
Fernando PardalPathology Department, Braga Hospital, Sete Fontes, São Victor, 4710-243 Braga, Portugal.
Mesquita RodriguesColoproctology Unit, Braga Hospital, Sete Fontes, São Victor, 4710-243 Braga, Portugal.
Adhemar Longatto-FilhoLife and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Campus of Gualtar, 4710-057 Braga, Portugal ; ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Campus of Gualtar, 4710-057 Braga, Portugal ; Laboratory of Medical Investigation (LIM) 14, Faculty of Medicine, University of Sao Paulo, 01246-903 São Paulo, SP, Brazil ; Molecular Oncology Research Centre, 14784-400 Barretos, SP, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colorectal cancer is one of the most common malignancies and a leading cause of cancer death worldwide. Molecular markers may improve clinicopathologic staging and provide a basis to guide novel therapeutic strategies which target specific tumour-associated molecules according to individual tumour biology; however, so far, no ideal molecular marker has been found to predict disease progression. We tested Ki-67 proliferation marker in primary and lymph node metastasis of CRC. We observed a statistical significant difference between the positive rates of neoplastic cells positively stained by Ki-67 in both sites, with remarkable increased number of Ki-67 positive cells in primary tumor cells compared to cancer cells that invaded lymph nodes. We can speculate that the metastatic CRC in lymph node can be more resistant to the drugs that target cellular division.

Indexed as

Colorectal NeoplasmsGene Expression Regulation, NeoplasticDisease-Free SurvivalFemaleHumansKi-67 AntigenLymphatic MetastasisMalePredictive Value of TestsSurvival RateKi-67 Antigen

Identifiers

PMID26448927
PMCPMC4584044

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.